Titan Pharmaceuticals, Inc. (de)

-0.07 (-6.67%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)8.60M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.09 Million
Adjusted EPS-$0.35
See more estimates
10-Day MA$0.99
50-Day MA$1.22
200-Day MA$1.96
See more pivots

Titan Pharmaceuticals, Inc. (de) Stock, NASDAQ:TTNP

400 Oyster Point Boulevard, Suite 505, South San Francisco, California 94080-1958
United States of America
Phone: +1.650.244.4990
Number of Employees: 12


Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.